Full Schedule

7:00 AM – 5:00 PM GMT

Registration
Location: Foyer

8:30 AM – 12:30 PM GMT

2023 Scientific Program Committee Meeting
Location: Room B

8:30 AM – 12:30 PM GMT

Principles of Pharmacoepidemiology
Location: Room A

Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Speaker: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS

Preconf Course

12:30 PM – 1:30 PM GMT

Lunch
Location: Foyer

1:30 PM – 5:30 PM GMT

Advanced Methods: Multi-database Networks: practical approaches to support the ‎journey from RWD to RWE
Location: Room A

Moderator: Deborah Layton, PhD, FISPE – PEPI Consultancy Limited

Speaker: Christian Reich, MD – Observational Health Data Sciences and Informatics

Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen

Speaker: Daniel R. Morales, MBChB, BMSc, PhD, MRCP, MRCGP – European Medicines Agency

Preconf Course

5:30 PM – 7:00 PM GMT

Welcome Reception
Location: Vox Club

8:00 AM – 9:00 AM GMT

Exhibits/Poster viewing
Location: Room B

8:00 AM – 5:00 PM GMT

Registration
Location: Foyer

9:00 AM – 9:15 AM GMT

Welcome and Introductions
Location: Room A

9:15 AM – 11:00 AM GMT

Real Time Use of Real-World Data for Decision-Making
Location: Room A

Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland

Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.

Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland

Speaker: Menno van der Elst (he/him/his) – Dutch Medicines ‎Evaluation Board‎

Plenary

11:00 AM – 11:30 AM GMT

Coffee break/Exhibit/Poster Viewing
Location: Room A

11:30 AM – 1:15 PM GMT

Pandemic Driven (Real-World) Data Shifts
Location: Room A

Moderator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands

Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research

Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine

Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University

Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen

Plenary

Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands ### 1061395###Moderator###Professor RWD for decision making on medicines###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands###
Moderator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
### she/her/hers @@@ Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research ### 1046831###Moderator###Professor and Director###Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research###
Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
### he/him/his @@@ Anne M. Butler, PhD, MS – Washington University School of Medicine ### 1062638###Speaker###Assistant Professor###Washington University School of Medicine###
Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine
### @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Speaker###Assistant Professor###McGill University###
Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his @@@ Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen ### 1302750###Speaker###Professor###Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen###
Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
###

1:15 PM – 2:15 PM GMT

Lunch break/Exhibit/Poster Viewing
Location: Foyer/Room B

2:15 PM – 3:45 PM GMT

OP1-0 - Student Oral Presentations Session I
Location: Room A

Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida

Women and off-spring

2:15 PM – 3:45 PM GMT

OP1-1 - Hormone therapy and risk of venous thromboembolism in transgender women
Location: Room A

Presenting Author: Qi Zhang, MSPH (she/her/hers) – Department of Epidemiology, Emory University

Author: Michael Goodman, MD, MPH (he/him/his) – Emory University

Databases

2:15 PM – 3:45 PM GMT

OP1-2 - Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother–Infant Linkage in the Japan Medical Data Center Claims Database
Location: Room A

Presenting Author: Julie Barberio (she/her/hers) – Department of Epidemiology, Emory University

Author: Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc.

Author: Ashley I. Naimi, PhD – Department of Epidemiology, Emory University

Author: Rachel E. Patzer, PhD – Department of Epidemiology, Emory University

Author: Christopher Kim, PhD – Center for Observational Research, Amgen Inc.

Author: Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA

Databases

2:15 PM – 3:45 PM GMT

OP1-3 - Determinants of vaccination and willingness to vaccinate against COVID-19 among pregnant and postpartum women during the third wave of the pandemic: A European Multinational cross-sectional survey
Location: Room A

Presenting Author: Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Author: Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Author: Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway

Author: Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Author: Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Author: Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Author: Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands

Author: Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK

Author: David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Author: Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Author: Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Vaccines

Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland ### 1900285###Presenting Author###PhD student###Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland###
Presenting Author: Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
### she/her/hers @@@ Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359620###Author###PhD student###Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###
Author: Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway ### 1063106###Author###PhD student###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway###
Author: Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway
### @@@ Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659156###Author###Midwife and Professor###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###
Author: Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659150###Author###PhD student###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###
Author: Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359633###Author###Pharmacist###Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###
Author: Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands ### 1900305###Author###Teratology information specialist###Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands###
Author: Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands
### @@@ Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK ### 1900306###Author###Senior Medical Information Scientist###UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK###
Author: Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK
### @@@ David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359631###Author###Head of department###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###
Author: David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium ### 1900303###Author###Pharmacist and researcher###Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium###
Author: Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
### @@@ Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland ### 1900290###Author###Head of BIHAM Pharmacy###Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland###
Author: Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
###

2:15 PM – 3:45 PM GMT

OP1-4 - Distinguishing between indications for use of medications in administrative data sources Application to pregabalin and gabapentin A contribution from the ConcePTION project
Location: Room A

Presenting Author: Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France

Author: Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand

Author: Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Author: Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.

Author: Claudia C. Bartolini – ARS Toscana

Author: Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France

Author: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy

Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki

Author: Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea

Author: Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France

Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Author: Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy

Author: Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

Author: Joan K. Morris – St George's, University of London, London

Author: Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy

Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Author: Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy

Author: Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY

Author: Christine Damase-Michel, PhD, PharmD – Université Toulouse III

Medications in Pregnancy & Lactation (MiPaL)

Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France ### 1359716###Presenting Author###Postdoctoral researcher###Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France###
Presenting Author: Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France
### @@@ Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand ### 1900353###Author###Medical Doctor###Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand###
Author: Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand
### @@@ Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1900337###Author###Researcher###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France. ### 1900336###Author###Postdoctoral researcher###Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.###
Author: Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.
### @@@ Claudia C. Bartolini – ARS Toscana ### 1063227###Author###Researcher###ARS Toscana###
Author: Claudia C. Bartolini – ARS Toscana
### @@@ Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1658844###Author###Statistician###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###
Author: Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy ### 1302758###Author###Head of Unit at ARS Toscana, Florence, Italy###ARS Toscana, Florence, Italy###
Author: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
### she/her/hers @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###
Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea ### 1359730###Author###professor###Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea###
Author: Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea
### @@@ Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1358268###Author###Head of Statistics and Data management###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###
Author: Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###
Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy ### 1900338###Author###Specialist in health statistics and biometrics###Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy###
Author: Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy
### @@@ Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1359729###Author###Data manager, statistician###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###
Author: Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Joan K. Morris – St George's, University of London, London ### 1900343###Author###Professor###St George's, University of London, London###
Author: Joan K. Morris – St George's, University of London, London
### @@@ Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy ### 1359720###Author###Registry Leader, IMER Registry###Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy###
Author: Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy ### 1359270###Author###Researcher###Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy###
Author: Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy
### @@@ Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY ### 1358153###Author###Professor###Worldwide Medical and Safety, Pfizer Inc., New York, NY###
Author: Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY
### @@@ Christine Damase-Michel, PhD, PharmD – Université Toulouse III ### 1358255###Author###Associate Professor in Pharmacology###Université Toulouse III###
Author: Christine Damase-Michel, PhD, PharmD – Université Toulouse III
###

2:15 PM – 3:45 PM GMT

OP1-5 - Preventative association of antidepressant treatment in pregnant women with eating disorders on antenatal mental outcomes- results from the Norwegian Mother, Father, and Child Cohort Study
Location: Room A

Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway

Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo

Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Medications in Pregnancy & Lactation (MiPaL)

Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway ### 1900335###Presenting Author###PhD-student###Department of Pharmacy, University of Oslo, Oslo, Norway###
Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway
### @@@ Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo ### 1655801###Author###Postdoctoral Fellow###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo###
Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###
Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
###

2:15 PM – 3:45 PM GMT

OP1-6 - Prenatal exposure to antipsychotic medication and neurocognitive impairment among children: A Nordic cohort study
Location: Room A

Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet

Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health

Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway

Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales

Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki

Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health

Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia

Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet

Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health

Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

Author: Helga Zoega – University of New South Wales - Sydney

Medications in Pregnancy & Lactation (MiPaL)

Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1062978###Presenting Author###PhD candidate###School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###
Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1062759###Author###Researcher###Centre for Pharmacoepidemiology, Karolinska Institutet###
Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Vidar Hjellvik, PhD – Norwegian Institute of Public Health ### 1358617###Author###Statistician###Norwegian Institute of Public Health###
Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health
### @@@ Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1360037###Author###Biostatistician###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###
Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### she/her/hers @@@ Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway ### 1360035###Author###Professor, consultant neurologist###NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway###
Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway
### @@@ Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1062595###Author###PhD candidate###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###
Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales ### 1359563###Author###Senior Biostatistician###School of Population Health, University of New South Wales###
Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales
### he/him/his @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###
Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia ### 1358233###Author###Senior Research Fellow###National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia###
Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
### she/her/hers @@@ Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ### 1360225###Author###Statistician###Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden###
Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
### he/him/his @@@ Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health ### 1358431###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health###
Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###
Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1063034###Author###Chief physician, professor###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###
Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia ### 1358403###Author###Professor###School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia###
Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
### @@@ Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1358377###Author###Associate professor###Centre for Pharmacoepidemiology, Karolinska Institutet###
Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1659382###Author###Statistician###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###
Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### @@@ Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health ### 1063219###Author###Senior researcher###Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health###
Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
### @@@ Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1900239###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###
Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Helga Zoega – University of New South Wales - Sydney ### 1358124###Author###Associate professor/professor###University of New South Wales - Sydney###
Author: Helga Zoega – University of New South Wales - Sydney
###

3:45 PM – 4:15 PM GMT

Coffee break/Exhibit/Poster Viewing
Location: Foyer/Room B

4:15 PM – 5:45 PM GMT

OP2-0 - Student Oral Presentations Session II
Location: Room A

Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University

Cardiovascular medications and outcomes

4:15 PM – 5:45 PM GMT

OP2-1 - Non-adherence to Direct Oral Anticoagulants among new users and old users in patients with atrial fibrillation in French clinical practice
Location: Room A

Presenting Author: Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium

Author: Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium

Author: Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium

Adherence

Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium ### 1900255###Presenting Author###MPharm, PhD student###1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium###
Presenting Author: Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
### @@@ Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium ### 1900256###Author###Full professor###1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium###
Author: Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium
### @@@ Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium ### 1900257###Author###Associate professor###1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium###
Author: Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
###

4:15 PM – 5:45 PM GMT

OP2-2 - Impact of Myocardial Infarction on Statin Adherence among Medicaid Beneficiaries in 14 States from 2001 to 2015
Location: Room A

Presenting Author: Courtney A. Johnson, MPH (she/her/hers) – Brown University

Author: Theresa I. Shireman, PhD (she/her/hers) – Brown University

Author: Amal N. Trivedi, MD, MPH – Brown University

Author: Omar Galárraga, PhD (he/him/his) – Brown University

Adherence

4:15 PM – 5:45 PM GMT

OP2-3 - Comparing the effect of Sacubitril/Valsartan Versus renin-angiotensin system (RAS) blockade in time to first heart failure exacerbation
Location: Room A

Presenting Author: Yasmin Elsobky, B.Pharm.SCi, MS (she/her/hers) – ALNAS Hospital

Author: Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital

Author: David Bates, MD (he/him/his) – Brigham and Women's Hospital

Comparative Effectiveness Research (CER)

4:15 PM – 5:45 PM GMT

OP2-5 - Modifiable statin characteristics associated with potential statin-related prescribing cascades in a large commercial insurance claims data of adult statin initiators
Location: Room A

Presenting Author: Grace (Hsin Min) Wang (she/her/hers) – University of Florida College of Pharmacy

Author: Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer

Author: Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA

Author: Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy

Geriatric Pharmacoepidemiology

4:15 PM – 5:45 PM GMT

OP2-4 - Effects of Antihypertensive Medications on the Risk of Alzheimer’s Disease and Other Dementias: A Machine Learning Approach
Location: Room A

Author: Xiaomo Xiong, MS – College of Pharmacy, University of South Carolina

Author: Sam Li, PhD – University of Tennessee Health Science Center

Author: Xiaoxia Wang – University of South Carolina

Author: Gang Lv, MD – Chinese PLA General Hospital

Presenting Author: Kevin Lu, PhD, FISPE – University of South Carolina

Comparative Effectiveness Research (CER)

4:15 PM – 5:45 PM GMT

OP2-6 - Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study
Location: Room A

Presenting Author: Oliver W. Scott, BHSc (first class hons) – University of Auckland

Author: Sandar TinTin, PhD – University of Auckland

Author: Sixten Harborg, PhD/MD student – Aarhus University

Author: Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board

Author: Ross Lawrenson, MD – University of Waikato

Author: Mark Elwood, MD – University of Auckland

Cancer

5:45 PM – 6:00 PM GMT

Closing Remarks
Location: Room A

6:30 PM – 7:30 PM GMT

Student/Early Career Professionals Meet & Greet
Location: Offsite

8:00 AM – 9:00 AM GMT

Exhibits/Poster viewing
Location: Room B

8:00 AM – 5:00 PM GMT

Registration
Location: Foyer

9:00 AM – 10:45 AM GMT

Real-World Data for Precision Medicine: A Pharmacoepidemiological Perspective
Location: Room A

Moderator: Maurizio Sessa, PharmD – University of Copenhagen

Moderator: Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania

Speaker: Andrew Bate – GlaxoSmithKline

Speaker: Larus S. Gudmundsson (he/him/his) – University of Iceland

Speaker: David O. Arnar – University of Iceland

Plenary

10:45 AM – 11:15 AM GMT

Coffee break/Exhibit/Poster Viewing
Location: Foyer/Room B

11:15 AM – 1:00 PM GMT

Future Innovation and Outlook for the Field of Pharmacoepidemiology
Location: Room a

Moderator: Andrew Bate – GlaxoSmithKline

Moderator: Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute

Speaker: Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK)

Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Speaker: Jamie Geier (she/her/hers) – Novartis Pharma AG

Plenary

1:00 PM – 2:00 PM GMT

Lunch break/Exhibit/Poster Viewing
Location: Foyer/Room B

2:00 PM – 3:30 PM GMT

OP3-0 - Student Oral Presentations Session III
Location: Room A

Moderator: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland

Moderator: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet

Drug utilization

2:00 PM – 3:30 PM GMT

OP3-2 - Disparities in the uptake of newer anticoagulant therapies for atrial fibrillation by race, ethnicity and social vulnerability in Medicare fee-for-service data
Location: Room a

Presenting Author: Kamika Reynolds, PhD – Sanofi

Author: Chintan Dave, PharmD, PhD – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

Drug Utilization/Health Services Research

2:00 PM – 3:30 PM GMT

OP3-3 - New and persistent benzodiazepine use associated with surgery
Location: Room A

Presenting Author: Þorsteinn Ívar Albertsson, BSc (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland

Author: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland

Author: Sigurbergur Kárason, MD, PhD, EMPH – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.

Author: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.

Drug Utilization/Health Services Research

Þorsteinn Ívar Albertsson, BSc (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland ### 1900384###Presenting Author###Student###Faculty of Medicine, University of Iceland, Reykjavík, Iceland###
Presenting Author: Þorsteinn Ívar Albertsson, BSc (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland
### he/him/his @@@ Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland ### 1900348###Author###Assistant Professor, University of Iceland; Clinical Pharmacist, Landspitali University Hospita.###Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland###
Author: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland
### she/her/hers @@@ Sigurbergur Kárason, MD, PhD, EMPH – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900385###Author###Professor, University of Iceland; Head of Anaesthesia, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###
Author: Sigurbergur Kárason, MD, PhD, EMPH – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### @@@ Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900347###Author###Professor, University of Iceland; Chief Physician, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###
Author: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### he/him/his

2:00 PM – 3:30 PM GMT

OP3-4 - Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Location: Room A

Presenting Author: Jeff Y. Yang, MSPH (he/him/his) – GSK

Author: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Author: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health

Author: Michael Hudgens, PhD – Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Author: James D. Lewis, MD MSCE – Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania

Author: Michael D. Kappelman, MD, MPH – Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC

Drug Utilization/Health Services Research

Jeff Y. Yang, MSPH (he/him/his) – GSK ### 1062851###Presenting Author###Associate Director, Epidemiology###GSK###
Presenting Author: Jeff Y. Yang, MSPH (he/him/his) – GSK
### he/him/his @@@ Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062592###Author###Associate Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###
Author: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### she/her/hers @@@ Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health ### 1046824###Author###Associate Professor###UNC Chapel Hill Gillings School of Global Public Health###
Author: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health
### she/her/hers @@@ Michael Hudgens, PhD – Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1358428###Author###Professor and Associate Chair###Gillings School of Global Public Health, University of North Carolina at Chapel Hill###
Author: Michael Hudgens, PhD – Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### @@@ James D. Lewis, MD MSCE – Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania ### 1900328###Author###Professor of Medicine and Epidemiology###Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania###
Author: James D. Lewis, MD MSCE – Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania
### @@@ Michael D. Kappelman, MD, MPH – Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC ### 1359502###Author###Professor###Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC###
Author: Michael D. Kappelman, MD, MPH – Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
###

2:00 PM – 3:30 PM GMT

OP3-5 - Evaluation of Adverse Drug Reaction and Drug-drug Interaction Profile in PLHIV after 60 months of Initiation of ART: A Cross-Sectional Study
Location: Room A

Presenting Author: Basavaraj Ramappa Poojar, Msc Medical Pharmacology, Final year PhD (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore

Author: Ashok Shenoy K (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore

Author: Ashwin Kamath, MD (he/him/his) – Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal

Author: John Ramapuram (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore

Author: Sathish B Rao (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore

Drug-Drug Interaction

2:00 PM – 3:30 PM GMT

OP3-6 - Post-Acute Care Setting after Hip Fracture Hospitalization and Subsequent Opioid Use in Older Adults
Location: Room A

Presenting Author: Meghan Cupp Buxton, BSc, MPH (she/her/hers) – Department of Epidemiology, Brown University School of Public Health

Author: Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health

Author: Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA

Author: Melissa R. Riester, PharmD – Brown University School of Public Health

Author: Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center

Author: Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health

Author: Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health

Geriatric Pharmacoepidemiology

Meghan Cupp Buxton, BSc, MPH (she/her/hers) – Department of Epidemiology, Brown University School of Public Health ### 1655731###Presenting Author###PhD Candidate###Department of Epidemiology, Brown University School of Public Health###
Presenting Author: Meghan Cupp Buxton, BSc, MPH (she/her/hers) – Department of Epidemiology, Brown University School of Public Health
### she/her/hers @@@ Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health ### 1358486###Author###Associate Professor###Department of Epidemiology, Brown University School of Public Health###
Author: Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health
### @@@ Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA ### 1062830###Author###Assistant Professor###Brown University School of Public Health, Providence, Rhode Island, USA###
Author: Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA
### she/her/hers @@@ Melissa R. Riester, PharmD – Brown University School of Public Health ### 1302727###Author###Research Scientist###Brown University School of Public Health###
Author: Melissa R. Riester, PharmD – Brown University School of Public Health
### @@@ Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center ### 1659409###Author###Associate Professor of Medicine###Department of Medicine, Beth Israel Deaconess Medical Center###
Author: Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center
### @@@ Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health ### 1655733###Author###Data Science Analyst###Department of Health Services, Policy, and Practice, Brown University School of Public Health###
Author: Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health
### @@@ Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health ### 1302736###Author###Associate Professor###Brown University School of Public Health###
Author: Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health
### he/him/his

3:30 PM – 4:00 PM GMT

Coffee break/Exhibit/Poster Viewing
Location: Foyer/Room B

4:00 PM – 5:30 PM GMT

OP4-0 - Student Oral Presentations Session IV
Location: Room A

Moderator: Deborah Layton, PhD, FISPE – PEPI Consultancy Limited

Moderator: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway

Informing regulators & improving methods

4:00 PM – 5:30 PM GMT

OP4-1 - Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines - a multistakeholder perspective
Location: Room A

Presenting Author: Christine C. van Hattem, MSc – Utrecht University

Author: Amos de Jong, Msc – Utrecht University

Author: Jolien S. de Groot, MD, PhD – Dutch Medicines Evaluation Board

Author: Lourens T. Bloem, PharmD, PhD (he/him/his) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Cancer

4:00 PM – 5:30 PM GMT

OP4-2 - Review of studies evaluating the effectiveness of risk minimization measures assessed by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency during 2016-2021
Location: Room A

Presenting Author: Renske Grupstra (she/her/hers) – Utrecht University

Author: Thomas Goedecke, Dr. – European Medicines Agency

Author: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Comparative Effectiveness Research (CER)

4:00 PM – 5:30 PM GMT

OP4-3 - Description of the delay in completion of studies that evaluate the effectiveness of additional risk minimization measures
Location: Room A

Presenting Author: Sharon CM Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.

Author: Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.

Author: Sabine MJM Straus, MD, PhD – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.

Author: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Author: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Benefit Risk Assessment, Communication and Evaluation (BRACE)

Sharon CM Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. ### 1659067###Presenting Author###PhD candidate###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.###
Presenting Author: Sharon CM Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### she/her/hers @@@ Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. ### 1659068###Author###Senior Pharmacovigilance assessor###Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.###
Author: Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### @@@ Sabine MJM Straus, MD, PhD – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands. ### 1094834###Author###Chair of PRAC, associate professor###Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.###
Author: Sabine MJM Straus, MD, PhD – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.
### @@@ Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University ### 1061395###Author###Associate professor###Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University###
Author: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University
### @@@ Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University ### 1360157###Author###Professor###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University###
Author: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### she/her/hers

4:00 PM – 5:30 PM GMT

OP4-4 - Pragmatic SIMEX-type method to correct for measurement error in time-varying prescription-based exposures
Location: Room A

Presenting Author: Steve Ferreira Guerra – McGill University

Author: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Author: Michal Abrahamowicz, PhD – McGill University

Adherence

4:00 PM – 5:30 PM GMT

OP4-5 - Effect of COVID-19 vaccines on post-COVID cardiac and thromboembolic complications
Location: Room A

Presenting Author: Núria Mercadé Besora (she/her/hers) – IDIAP Jordi Gol

Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University

Author: Elena Roel, MD – Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)

Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Author: Clara Prats, PHD (she/her/hers) – Universitat Politècnica de Catalunya

Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford

Author: Martí Català Sabaté, PhD (he/him/his) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Vaccines

Núria Mercadé Besora (she/her/hers) – IDIAP Jordi Gol ### 1900320###Presenting Author###Data scientist###IDIAP Jordi Gol###
Presenting Author: Núria Mercadé Besora (she/her/hers) – IDIAP Jordi Gol
### she/her/hers @@@ Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University ### 1062615###Author###Professor of Pharmaco- and Device Epidemiology, Professor of RWE###University of Oxford, Erasmus MC University###
Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University
### he/him/his @@@ Elena Roel, MD – Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) ### 1360486###Author###PhD student###Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)###
Author: Elena Roel, MD – Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
### @@@ Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358614###Author###Lead Health Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###
Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### she/her/hers @@@ Clara Prats, PHD (she/her/hers) – Universitat Politècnica de Catalunya ### 1358939###Author###Professor and Researcher###Universitat Politècnica de Catalunya###
Author: Clara Prats, PHD (she/her/hers) – Universitat Politècnica de Catalunya
### she/her/hers @@@ Annika M. Jödicke, PhD (she/her/hers) – University of Oxford ### 1358980###Author###Senior Researcher in Pharmacoepidemiology###University of Oxford###
Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford
### she/her/hers @@@ Martí Català Sabaté, PhD (he/him/his) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1659148###Author###Senior Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###
Author: Martí Català Sabaté, PhD (he/him/his) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### he/him/his

4:00 PM – 5:30 PM GMT

OP4-6 - Common comorbidities and COVID-19 mortality: an empirical comparison of primary care alone vs additional hospital data linkage for association analyses
Location: Room A

Presenting Author: Junqing Xie, MBBS, MSc, DPhil – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Author: Yaqing Gao, MPH – Oxford University

Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Author: Sara Khalid, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Author: Gary S. Collins, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford

Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford

Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University

Databases

Junqing Xie, MBBS, MSc, DPhil – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358612###Presenting Author###DPhil Candidate & Research Assistant###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###
Presenting Author: Junqing Xie, MBBS, MSc, DPhil – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### @@@ Yaqing Gao, MPH – Oxford University ### 1900270###Author###Doctoral student###Oxford University###
Author: Yaqing Gao, MPH – Oxford University
### @@@ Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358614###Author###Lead Health Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###
Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### she/her/hers @@@ Sara Khalid, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358353###Author###Associate Professor###Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###
Author: Sara Khalid, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### @@@ Gary S. Collins, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford ### 1358613###Author###Professor###Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford###
Author: Gary S. Collins, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford
### @@@ Annika M. Jödicke, PhD (she/her/hers) – University of Oxford ### 1358980###Author###Senior Researcher in Pharmacoepidemiology###University of Oxford###
Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford
### she/her/hers @@@ Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University ### 1062615###Author###Professor of Pharmaco- and Device Epidemiology, Professor of RWE###University of Oxford, Erasmus MC University###
Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University
### he/him/his

5:30 PM – 5:45 PM GMT

Closing Remarks & Adjournment
Location: Room A